A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
收藏NIAID Data Ecosystem2026-03-10 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2225595
下载链接
链接失效反馈官方服务：
资源简介：
This study is to define the safety profile and to determine the Maximal tolerated dose regimen and preliminary efficacy of AbGn-107 administered every 14 days (Q2W regimen) or 28 days (Q4W regimen) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal, pancreatic or biliary cancer.
创建时间：
2017-04-15
